Search Result

Results for "

CCKA

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (1) CCR (2) Cholecystokinin Receptor (16) Drug Isomer (1) P-glycoprotein (2) Reference Standards (2) Small Interfering RNA (siRNA) (1)
By Research Areas:	Endocrinology (6) Infection (1) Inflammation/Immunology (2) Metabolic Disease (12) Neurological Disease (3)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) siRNAs (1)

Inhibitors & Agonists

Peptides

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective *CCK-A* full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-128878

Dexloxiglumide	Cholecystokinin Receptor P-glycoprotein	Metabolic Disease Endocrinology
Dexloxiglumide is an orally active and selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide is the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Dexloxiglumide exhibits moderate Caco-2 permeability that is polarized, concentration dependent, and pH dependent. Dexloxiglumide increases MRP1-substrate fluorescein uptake. Dexloxiglumide can be studied in research for gastrointestinal diseases and tumors .

HY-103355

YM022 2 Publications Verification	CCR	Metabolic Disease
YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the K_i values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .

HY-118194

A-65186	Cholecystokinin Receptor	Others
A-65186 is a CCK-A receptor antagonist with the activity of inhibiting CCK8-induced amylase secretion. A-65186 has high binding affinity for pancreatic CCK-A receptors, is more than 500 times more selective for CCK-A receptors than for CCK-B receptors, and can inhibit CCK8-induced amylase secretion.

HY-123434

PD-149164	Cholecystokinin Receptor	Metabolic Disease Endocrinology
PD-149164 is a potent agonist of cholecystokinin B (CCK-B) receptor, with IC₅₀ values of 0.083 nM and 75 nM in binding assay to CCK-B and CCK-A .

HY-U00363

CHEMBL333994 FK-480	Cholecystokinin Receptor	Endocrinology
CHEMBL333994 (FK-480) is a potent and orally active Cholecystokinin A receptor *(CCK-A* receptor) antagonist, with an IC₅₀** of 0.67 nM. CHEMBL333994 selectively antagonizes peripheral CCK receptors. CHEMBL333994 increases CCK mRNA level. CHEMBL333994 can be used for research of chronic pancreatitis .

HY-U00062

Tarazepide	Cholecystokinin Receptor	Metabolic Disease Endocrinology
Tarazepide is a potent and specific *CCK-A* receptor antagonist.

HY-111918

A71378	Cholecystokinin Receptor	Metabolic Disease
A71378 is a selectivity CCK-A receptor agonist the IC₅₀ values of 0.4 nM, 300 nM, and 1,200 nM for the pancreatic CCK-A, cortical CCK-B, and gastrin receptor, respectively. A71378 elicits pancreatic amylase secretion (EC₅₀ = 0.16 nM) and ileal muscle contraction (EC₅₀ = 3.7 nM) .

HY-U00387

CCK-A receptor inhibitor 1	Cholecystokinin Receptor	Metabolic Disease Endocrinology
CCK-A receptor inhibitor 1 is a cholecystokinin A (CCK-A) receptor inhibitor with a binging IC₅₀ of 340 nM.

HY-123182

PD-140548	Cholecystokinin Receptor	Neurological Disease
PD-140548 is a selective cholecystokinin (CCKA) receptor antagonist. PD-140548 can be used in schizophrenia research .

HY-119127

TP-680	Cholecystokinin Receptor	Metabolic Disease
TP-680 is a cholecystokinin receptor antagonist. TP-680 binds 1510 times more strongly to rat pancreatic *CCK_A* receptors (IC₅₀=1.2 nM) than to rat brain CCK_B receptors (IC₅₀=1812.5 nM). TP-680 can be used in the study of gastrointestinal diseases .

HY-RS02074

CCKAR Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
CCKAR Human Pre-designed siRNA Set A contains three designed siRNAs for CCKAR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

CCKAR Human Pre-designed siRNA Set A CCKAR Human Pre-designed siRNA Set A

HY-169065

Antibacterial agent 241	Bacterial	Infection
Antibacterial agent 241 is a histidine kinase (HK) inhibitor, with IC₅₀ values of 14 μM and 238 μM for CckA and PhoQ, respectively. Antibacterial agent 241 shows moderate antibacterial activity against E. coli DC2, Bacillus cereus, and Bacillus subtilis, with a MIC range of 12-74 μg/mL .

HY-U00363A

(rac)-CHEMBL333994 (rac)-FK-480	Cholecystokinin Receptor Drug Isomer	Inflammation/Immunology
(rac)-CHEMBL333994 is the racemate of CHEMBL333994 (HY-U00363). CHEMBL333994 is a potent and orally active Cholecystokinin A receptor *(CCK-A* receptor) antagonist, with an IC₅₀** of 0.67 nM. CHEMBL333994 selectively antagonizes peripheral CCK receptors. CHEMBL333994 increases CCK mRNA level. CHEMBL333994 can be used for research of chronic pancreatitis .

HY-118665

L-736380	Cholecystokinin Receptor	Metabolic Disease
L-736380 is a high affinity CCK-B (cholecystokinin B receptor) receptor antagonist, with IC₅₀ values of 0.054 nM and 400 nM for CCK-B and CCK-A, respectively. L-736380 dose-dependently inhibits gastric acid secretion in anesthetized rats (ID₅₀, 0.064 mg/kg) and ex vivo binding of [125I]CCK-8S in BKTO mice brain membranes (ED₅₀, 1.7 mg/kg) .

HY-129516

A-70874	Cholecystokinin Receptor	Metabolic Disease
A-70874 is a tyrosine-free tetrapeptide analog of cholecystokinin (30-33) (CCK-4). A-70874 is an agonist that stimulates pancreatic amylase release and a partial agonist that stimulates pancreatic phosphoinositide decomposition. A-70874 has an IC₅₀ of 4.9 nM for the guinea pig pancreatic CCK receptor. Cholecystokinin (CCK) receptors are divided into CCK-A (digestive tract) and CCK-B (brain). A-70874 has an affinity of 1.6 μM for the CCK-B/gastrin receptor .

HY-128878R

Dexloxiglumide (Standard)	Cholecystokinin Receptor P-glycoprotein Reference Standards	Metabolic Disease Endocrinology
Dexloxiglumide (Standard) is the analytical standard of Dexloxiglumide. This product is intended for research and analytical applications. Dexloxiglumide is an orally active and selective cholecystokinin type A (CCKA) receptor antagonist. Dexloxiglumide is the active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). Dexloxiglumide exhibits moderate Caco-2 permeability that is polarized, concentration dependent, and pH dependent. Dexloxiglumide increases MRP1-substrate fluorescein uptake. Dexloxiglumide can be studied in research for gastrointestinal diseases and tumors .

HY-P1994A

JMV 170	Cholecystokinin Receptor	Neurological Disease
JMV 170, a CCK derivative, is a selective CCK-B agonist. JMV 170 binds to the CCK-B receptor with a 10-fold higher affinity than to the *CCK-A* receptor. JMV 170 shows contractile effects on pig smooth muscle cells with an EC₅₀ of 9 pmol/L .

HY-103355R

YM022 (Standard)	Reference Standards CCR	Metabolic Disease
YM022 (Standard) is the analytical standard of YM022 (HY-103355). This product is intended for research and analytical applications. YM022 is a highly potent, selective and orally active gastrin/cholecystokinin (CCK)-B receptor (CCK-BR) antagonist. YM022 shows the K_i values of 68 pM and 63 nM for CCK-B and CCK-A receptor, respectively . YM022 can inhibit gastrin-induced gastric acid secretion and histidine decarboxylase activation in vivo .

HY-116260

RP-69758	Cholecystokinin Receptor	Neurological Disease Inflammation/Immunology
RP-69758 is a potent and selective non-peptide cholecystokinin-B (CCK_B)/gastrin receptor antagonist. RP-69758 exhibits >200-fold selectivity for CCK_B over CCK_A receptors. RP-69758 antagonizes CCK-8-induced neuronal firing in rat hippocampal slices. RP-69758 inhibits Pentagastrin (HY-A0261)-induced gastric acid secretion in the rat. RP-69758 can be used for neurological disorders and gastrointestinal disease research .

Cat. No.	Product Name	Target	Research Area

HY-P1096

A71623	Cholecystokinin Receptor	Metabolic Disease
A71623, a CCK-4-based peptide, is a potent and highly selective *CCK-A* full agonist. The IC₅₀s for A-71623 are 3.7 nM in guinea pig pancreas (CCK-A) and 4500 nM in cerebral cortex (CCK-B) in radioligand binding assays, respectively .

HY-P1994A

JMV 170	Cholecystokinin Receptor	Neurological Disease
JMV 170, a CCK derivative, is a selective CCK-B agonist. JMV 170 binds to the CCK-B receptor with a 10-fold higher affinity than to the *CCK-A* receptor. JMV 170 shows contractile effects on pig smooth muscle cells with an EC₅₀ of 9 pmol/L .

CCKAR Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
CCKAR Human Pre-designed siRNA Set A contains three designed siRNAs for CCKAR gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.